New treatment for autoimmune diseases using intranasal therapy
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity
This study is testing a new nasal treatment that helps the immune system learn to ignore certain harmful proteins in autoimmune diseases, like autoimmune myocarditis, so that patients can feel better without just masking their symptoms.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10903763 on NIH RePORTER |
What this research studies
This research focuses on developing a novel intranasal therapy that targets autoimmune diseases by programming the immune system to tolerate specific autoantigens. The approach involves creating a biomaterial that delivers autoantigens and tolerance-inducing molecules directly to the nasal mucosa, which helps to generate regulatory T cells that can suppress harmful immune responses. By using this method, the research aims to provide a more effective treatment for conditions like autoimmune myocarditis, moving beyond traditional immunosuppressive therapies that only alleviate symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases, particularly those experiencing autoimmune myocarditis.
Not a fit: Patients with non-autoimmune related conditions or those who do not have a specific autoimmune diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that specifically addresses the underlying causes of autoimmune diseases rather than just managing symptoms.
How similar studies have performed: While this approach is innovative, similar strategies targeting immune tolerance have shown promise in other contexts, suggesting potential for success in this novel application.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Wilson, David Scott — Johns Hopkins University
- Study coordinator: Wilson, David Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.